This is a single-center, randomized, double-blind, placebo-controlled, ascending,
single-infusion, sequential group study. Single, ascending doses will be administered to
approximately 64 subjects, with an option for 1 additional multi-dose cohort in approximately
8 subjects. The primary objective is to evaluate the safety of ANX005 administered as an
intravenous infusion as a single agent and in combination with intravenous immunoglobulin
(IVIg). The optional multi-dose cohort will evaluate either additional subjects at the
maximum tolerated dose or ANX005 administered as 2 infusions.